mTOR pathway activation in large vessel vasculitis.

CONCLUSIONS: We provided evidence that mTORC1 pathway has a central role in driving T cell inflammation and vascular lesions in LVV. Targeting mTORC pathway may represent a new therapeutic option in patients with LVV.
PMID: 30061014 [PubMed - as supplied by publisher]

Source: Journal of Autoimmunity - July 27, 2018 Category: Allergy & Immunology Authors: Maciejewski-Duval A, Comarmond C, Leroyer A, Zaidan M, Le Joncour A, Desbois AC, Fouret JP, Koskas F, Cluzel P, Garrido M, Cacoub P, Saadoun D Tags: J Autoimmun Source Type: research